Mid-term (4-7 years) Results of Matrix-Associated Stem Cell Transplantation (MAST) in Chondral Defects of the First Metatarsophalangeal Joint

Category: Midfoot/Forefoot Introduction/Purpose: Matrix-associated stem cell transplantation (MAST) has shown good short-term results for treatment of chondral defects at first metatarsophalangeal joint (MTP1). The aim of the study was to assess mid-term results (=4-year-follow- up). Methods: In a p...

Full description

Bibliographic Details
Main Authors: Martinus Richter MD, PhD, Stefan Zech MD, Stefan Meissner MD, Issam Naef
Format: Article
Language:English
Published: SAGE Publishing 2019-10-01
Series:Foot & Ankle Orthopaedics
Online Access:https://doi.org/10.1177/2473011419S00357
_version_ 1818260785625825280
author Martinus Richter MD, PhD
Stefan Zech MD
Stefan Meissner MD
Issam Naef
author_facet Martinus Richter MD, PhD
Stefan Zech MD
Stefan Meissner MD
Issam Naef
author_sort Martinus Richter MD, PhD
collection DOAJ
description Category: Midfoot/Forefoot Introduction/Purpose: Matrix-associated stem cell transplantation (MAST) has shown good short-term results for treatment of chondral defects at first metatarsophalangeal joint (MTP1). The aim of the study was to assess mid-term results (=4-year-follow- up). Methods: In a prospective consecutive non-controlled clinical follow-up study, 61 patients with 81 chondral defects at MTP1 that were treated with MAST from October 1, 2011 to October 31, 2014 were analysed. Degree of osteoarthritis, range of motion (ROM), size and location of the chondral defects, pedographic parameters, and the Visual Analogue Scale Foot and Ankle (VAS FA) before treatment and at follow-up were registered and analysed. Bone marrow aspirate was harvested from the ipsilateral pelvic bone marrow and centrifuged (10 minutes, 1,500 RPM). The supernatant was used to impregnate a collagen I/III matrix (Chondro-Guide). The matrix was fixed into the chondral defect with fibrin glue. Results: Following mean (range) values were registered at time of surgery: age 44 (35-72) years, VAS FA 49.4 (12.3-82.3), ROM 20.4/0/8.4° (dorsiflexion/plantarflexion), degree of osteoarthritis 1.9 (1-3). The 81 chondral defects were located as follows, dorsal metatarsal head, n=28 (35%), plantar metatarsal head, n=12 (15%); dorsal & plantar, n=21 (26%); medial sesamoid, n=14 (17%); lateral sesamoid, n=6 (7%)(two defects, n=14, three defects, n=3). The defect size was 0.9 (.5 - 3.0) cm2. Fifty-six patients (92%) completed follow-up at 62 (48-84) months. VAS FA increased to 82.5 (45.6-100; t-test, p<.01). ROM increased to 30.2/0/15.4 (p=.05). Degree of osteoarthritis decreased to 1.1 (0-3, p=.04) Conclusion: The surgical treatment of chondral defects at MTP1 including MAST led to improved clinical scores, ROM and degree of osteoarthritis after 4-7 years. No adverse effects of MAST were registered. Even though a control group is missing, we conclude that MAST is an effective method for the treatment of chondral defects at MTP1.
first_indexed 2024-12-12T18:36:51Z
format Article
id doaj.art-98fa22ce526c4835b41e2d2f663fe4f6
institution Directory Open Access Journal
issn 2473-0114
language English
last_indexed 2024-12-12T18:36:51Z
publishDate 2019-10-01
publisher SAGE Publishing
record_format Article
series Foot & Ankle Orthopaedics
spelling doaj.art-98fa22ce526c4835b41e2d2f663fe4f62022-12-22T00:15:46ZengSAGE PublishingFoot & Ankle Orthopaedics2473-01142019-10-01410.1177/2473011419S00357Mid-term (4-7 years) Results of Matrix-Associated Stem Cell Transplantation (MAST) in Chondral Defects of the First Metatarsophalangeal JointMartinus Richter MD, PhDStefan Zech MDStefan Meissner MDIssam NaefCategory: Midfoot/Forefoot Introduction/Purpose: Matrix-associated stem cell transplantation (MAST) has shown good short-term results for treatment of chondral defects at first metatarsophalangeal joint (MTP1). The aim of the study was to assess mid-term results (=4-year-follow- up). Methods: In a prospective consecutive non-controlled clinical follow-up study, 61 patients with 81 chondral defects at MTP1 that were treated with MAST from October 1, 2011 to October 31, 2014 were analysed. Degree of osteoarthritis, range of motion (ROM), size and location of the chondral defects, pedographic parameters, and the Visual Analogue Scale Foot and Ankle (VAS FA) before treatment and at follow-up were registered and analysed. Bone marrow aspirate was harvested from the ipsilateral pelvic bone marrow and centrifuged (10 minutes, 1,500 RPM). The supernatant was used to impregnate a collagen I/III matrix (Chondro-Guide). The matrix was fixed into the chondral defect with fibrin glue. Results: Following mean (range) values were registered at time of surgery: age 44 (35-72) years, VAS FA 49.4 (12.3-82.3), ROM 20.4/0/8.4° (dorsiflexion/plantarflexion), degree of osteoarthritis 1.9 (1-3). The 81 chondral defects were located as follows, dorsal metatarsal head, n=28 (35%), plantar metatarsal head, n=12 (15%); dorsal & plantar, n=21 (26%); medial sesamoid, n=14 (17%); lateral sesamoid, n=6 (7%)(two defects, n=14, three defects, n=3). The defect size was 0.9 (.5 - 3.0) cm2. Fifty-six patients (92%) completed follow-up at 62 (48-84) months. VAS FA increased to 82.5 (45.6-100; t-test, p<.01). ROM increased to 30.2/0/15.4 (p=.05). Degree of osteoarthritis decreased to 1.1 (0-3, p=.04) Conclusion: The surgical treatment of chondral defects at MTP1 including MAST led to improved clinical scores, ROM and degree of osteoarthritis after 4-7 years. No adverse effects of MAST were registered. Even though a control group is missing, we conclude that MAST is an effective method for the treatment of chondral defects at MTP1.https://doi.org/10.1177/2473011419S00357
spellingShingle Martinus Richter MD, PhD
Stefan Zech MD
Stefan Meissner MD
Issam Naef
Mid-term (4-7 years) Results of Matrix-Associated Stem Cell Transplantation (MAST) in Chondral Defects of the First Metatarsophalangeal Joint
Foot & Ankle Orthopaedics
title Mid-term (4-7 years) Results of Matrix-Associated Stem Cell Transplantation (MAST) in Chondral Defects of the First Metatarsophalangeal Joint
title_full Mid-term (4-7 years) Results of Matrix-Associated Stem Cell Transplantation (MAST) in Chondral Defects of the First Metatarsophalangeal Joint
title_fullStr Mid-term (4-7 years) Results of Matrix-Associated Stem Cell Transplantation (MAST) in Chondral Defects of the First Metatarsophalangeal Joint
title_full_unstemmed Mid-term (4-7 years) Results of Matrix-Associated Stem Cell Transplantation (MAST) in Chondral Defects of the First Metatarsophalangeal Joint
title_short Mid-term (4-7 years) Results of Matrix-Associated Stem Cell Transplantation (MAST) in Chondral Defects of the First Metatarsophalangeal Joint
title_sort mid term 4 7 years results of matrix associated stem cell transplantation mast in chondral defects of the first metatarsophalangeal joint
url https://doi.org/10.1177/2473011419S00357
work_keys_str_mv AT martinusrichtermdphd midterm47yearsresultsofmatrixassociatedstemcelltransplantationmastinchondraldefectsofthefirstmetatarsophalangealjoint
AT stefanzechmd midterm47yearsresultsofmatrixassociatedstemcelltransplantationmastinchondraldefectsofthefirstmetatarsophalangealjoint
AT stefanmeissnermd midterm47yearsresultsofmatrixassociatedstemcelltransplantationmastinchondraldefectsofthefirstmetatarsophalangealjoint
AT issamnaef midterm47yearsresultsofmatrixassociatedstemcelltransplantationmastinchondraldefectsofthefirstmetatarsophalangealjoint